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1. Introduction {#ehf212504-sec-0004}
===============

Patients with heart failure (HF) are inclined to protein catabolism because inflammatory cytokines are elevated and IGF‐1 is decreased.[1](#ehf212504-bib-0001){ref-type="ref"} Consequently, muscle mass and strength progressively decrease, and reduction in exercise tolerability progresses.[2](#ehf212504-bib-0002){ref-type="ref"}, [3](#ehf212504-bib-0003){ref-type="ref"}, [4](#ehf212504-bib-0004){ref-type="ref"} In patients with HF, declining exercise capacity not only leads to poor quality of life but also is a strong prognostic factor.[2](#ehf212504-bib-0002){ref-type="ref"}, [5](#ehf212504-bib-0005){ref-type="ref"} Patients with HF experience frequent hospitalizations due to exacerbation of HF, and physical function declines progressively especially during this period.[6](#ehf212504-bib-0006){ref-type="ref"} In the management of patients with acute HF (AHF), immobilization is caused by deterioration of haemodynamics and dyspnoea, which drives further protein wasting.[7](#ehf212504-bib-0007){ref-type="ref"} Early ambulation may prevent protein catabolism; however, in patients with AHF, no other proactive precaution against muscle wasting was established.[8](#ehf212504-bib-0008){ref-type="ref"}

Neuromuscular electrical stimulation (NMES) has been reported to preserve muscle mass in critically ill patients and patients with chronic HF.[9](#ehf212504-bib-0009){ref-type="ref"}, [10](#ehf212504-bib-0010){ref-type="ref"}, [11](#ehf212504-bib-0011){ref-type="ref"} Treatment with NMES also provides a similar gain in functional outcomes without adverse events when compared with conventional aerobic exercise training in chronic HF.[12](#ehf212504-bib-0012){ref-type="ref"}, [13](#ehf212504-bib-0013){ref-type="ref"} As NMES can induce muscle contraction without a patient\'s volitional effort, it will be applicable in patients with AHF who have exercise difficulty due to instability of haemodynamics or respiratory status. Even in the acute phase of AHF, NMES is likely to work preventively on protein catabolism, which may contribute to functional decline prevention and in turn improve long‐term prognosis. Despite the establishment of safety of NMES in patients in the intensive care unit and clinically stable patients with chronic HF,[10](#ehf212504-bib-0010){ref-type="ref"}, [11](#ehf212504-bib-0011){ref-type="ref"}, [14](#ehf212504-bib-0014){ref-type="ref"} it has not been examined in the acute phase of patients with AHF. The feasibility and safety of NMES in AHF should be examined because, in the early phase of hospitalization, patients with AHF often manifest circulatory and/or respiratory instability that may worsen with NMES. Therefore, the purpose of this study was to examine the feasibility of NMES in patients with AHF immediately after admission.

2. Methods {#ehf212504-sec-0005}
==========

2.1. Study population {#ehf212504-sec-0006}
---------------------

This was a randomized tester‐blinded trial to examine the feasibility of NMES during the acute phase of AHF. Patients who were admitted to Nagoya Ekisaikai Hospital due to AHF and had ambulatory ability before admission between October 2013 and July 2015 were consecutively enrolled in the study. Patients were eligible for inclusion if they met the modified Framingham criteria.[15](#ehf212504-bib-0015){ref-type="ref"} The exclusion criteria were as follows: peripheral arterial disease (Fontaine classification III), dialysis, psychiatric disease, neuromuscular disease, and dementia. Patients were also excluded if they had the following: (i) New York Heart Association functional class I or II, (ii) acute coronary syndrome, (iii) intra‐aortic balloon pump or extracorporeal membrane oxygenation, (iv) systolic blood pressure (BP) \< 80 mmHg even with inotropic or vasopressor support, (v) intubation, (vi) agitation requiring sedation physically or by medication, and (vii) severe ventricular arrhythmia.

Written informed consent was obtained from each patient. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in *a priori* approval by the human (ethics) subjects committee of Ekisaikai Hospital (approval number 2013‐024).

2.2. Neuromuscular electrical stimulation {#ehf212504-sec-0007}
-----------------------------------------

Patients were randomly assigned to either the NMES or control group, using stratified randomization by sex and left ventricular ejection fraction (LVEF) (LVEF ≥ 40% vs LVEF \< 40%) with a random number table upon admission by one independent person. In this study, whether NMES can be feasible or safely implemented in patients with AHF was investigated by showing that the preset feasibility criteria can be fulfilled and that there are no differences in haemodynamics and adverse effect between the NMES and control groups.

Patients received NMES on the bilateral quadriceps femoris and triceps surae, and the sessions were conducted during the entire hospitalization period 5 days per week, from Monday to Friday in both groups. The first session was performed on the day after admission.

In this study, we adopted the same NMES protocol described elsewhere.[16](#ehf212504-bib-0016){ref-type="ref"} We applied NMES with a variable‐frequency train that began with high‐frequency bursts (200 Hz), followed by low‐frequency stimulation (20 Hz). The stimulation consists of a direct electrical current for 0.4 s, followed by a pause lasting 0.6 s. Pulse groups consisting of 10 impulse trains were delivered at 30 s intervals during the session. As for intensity of stimulation, 10% of maximal voluntary contraction (MVC) was prescribed for the first and second pulse groups and 20% MVC for the third pulse group by setting electrical current adjust system, and repetitions of 10--10--20% MVC stimulation were prescribed throughout the session. Based on our previous study (unpublished data), the current intensity of 10% MVC on the quadriceps was determined at the level of heel lifting from a pillow placed under the knee in hook lying, and 20% MVC was determined at the level of lower leg lifting. The current intensities for the triceps surae were set at the same levels as those for the quadriceps. The duration of the session was set at 30 min and extended to 60 min on the basis of on the patient\'s tolerance. We have previously confirmed that the described protocol is acceptable and can be safely performed without causing an abnormal cardiovascular response and neuromuscular fatigue in community‐dwelling older adults (*n* = 20; mean age ± SD, 74 ± 5.8years; Sampei and Yamada, unpublished data, 2011). The control group was exposed to the same regimen of NMES with the intensity of stimulation set at a visible or palpable level of muscle contractions as judged objectively and subjectively. The surface electrodes (62 × 62 mm) were placed bilaterally on the vastus lateralis, vastus medialis, and triceps surae, and the detailed position of the electrodes was described elsewhere.[16](#ehf212504-bib-0016){ref-type="ref"}

During the session, electrocardiogram was continuously monitored to detect arrhythmias. BP and heart rate (HR) were measured before and 10, 20, and 30 min after the session started, and we reported BP and HR 30 min after the session started as time when session was completed enough. The intracardiac electrocardiogram was monitored in all patients with implantable cardioverter defibrillator or in those with pacemaker during the first session. Pain in the lower limb was also assessed on a visual analogue scale ranging from 0 to 10 cm during the NMES session.

2.3. Feasibility outcomes {#ehf212504-sec-0008}
-------------------------

Before the study implementation, we set the feasibility criteria as follows: (i) change in systolic BP \> ±20 mmHg during the first session; (ii) increase in HR \> + 20 b.p.m. during the first session; (iii) development of sustained ventricular arrhythmia, atrial fibrillation (AF), and paroxysmal supraventricular tachycardia during all sessions; (iv) incidence of new‐onset AF during the hospitalization period \< 40%; and (v) completion of the planned sessions by \>70% of patients. Acceptable ranges of change in systolic BP and HR were determined on the basis of clinical expert opinion. If the percentage to fill one of (i)--(iii) was under 20% of the total subjects and both (iv) and (v) was satisfied, we defined the feasibility of NMES as high.

2.4. Echocardiography {#ehf212504-sec-0009}
---------------------

All patients and examiners of echocardiography were masked to the treatment assignment. Echocardiography was performed with Vivid Q (GE Healthcare, Horten, Norway) just before and after the first session to examine the adverse haemodyanamic effect induced by NMES. Left ventricular end‐diastolic dimension (LVDd) and left atrial dimension (LAD) were measured from standard M‐mode, and LVEF was calculated with the biplane Simpson method. The tissue Doppler images of the mitral annulus movement were recorded in the apical four‐chamber view. Peak early transmitral velocity (*E*) was obtained from the transmitral flow, and peak early diastolic mitral annular velocity (*E*′) was also measured with pulsed‐wave Doppler. *E*/*E*′ was calculated to estimate the left ventricular filling pressure. Inferior vena cava diameter was also measured, and right atrial pressure (RAP) was estimated according to Guidelines for the Echocardiographic Assessment of the Right Heart in Adults, as follows:[17](#ehf212504-bib-0017){ref-type="ref"} inferior vena cava diameter ≤ 2.1 cm that collapses \>50% with a sniff, RAP of 3 mmHg; inferior vena cava diameter \> 2.1 cm that collapses \<50% with a sniff, RAP of 15 mmHg; and indeterminate cases in which the inferior vena cava diameter and collapse do not fit this paradigm, RAP of 8 mmHg. The peak velocity (in m/s) of the tricuspid valve regurgitant jet (*V*) was recorded from the apical four‐chamber window, and tricuspid regurgitation peak gradient (TRPG) was calculated by the Bernoulli equation: TRPG = 4(*V*)^2^.[17](#ehf212504-bib-0017){ref-type="ref"}

2.5. Laboratory examination {#ehf212504-sec-0010}
---------------------------

Haemoglobin, serum creatinine, serum albumin, and Brain natriuretic peptide levels were also measured within 24 h of hospitalization.

2.6. Statistical analysis {#ehf212504-sec-0011}
-------------------------

According to the estimated BP variability from a previous study,[18](#ehf212504-bib-0018){ref-type="ref"} a total sample size of 30 participants in each group would provide 90% power to detect BP difference of \>20 mmHg between the baseline BP and BP at 10, 20, and 30 min after the session started, using one‐way repeated‐measures analysis of variance test with 0.05 level of significance. Continuous variables were expressed as means ± standard deviations or medians with lower and upper quartiles as appropriate. Continuous variables were compared by *t*‐test or Mann--Whitney test as appropriate. Categorical variables were expressed as counts (percentage) compared by *χ* ^2^ or Fisher exact test. The changes in BP and HR during the first session were evaluated using one‐way repeated‐measures analysis of variance over time and compared using two‐way repeated‐measures analysis of variance between the NMES and control groups. Echocardiographic parameters before and after the first session were compared by paired *t*‐test. The primary outcome was the fulfilment of the feasibility criteria. In the haemodynamic change during the session, adverse events were also assessed as a secondary outcome.

All statistical analyses were performed using PASW Statistics 18 (SAS Institute, Cary, NC, USA), and a *P* value \< 0.05 was considered statistically significant.

3. Results {#ehf212504-sec-0012}
==========

3.1. Patient characteristics {#ehf212504-sec-0013}
----------------------------

The patient flow chart is depicted in *Figure* [*1*](#ehf212504-fig-0001){ref-type="fig"}. Among 372 subjects who were admitted for AHF in Nagoya Ekisaikai Hospital, 78 were allocated. Of these, four patients in the NMES group and one patient in the control group did not receive any sessions and were excluded from the analysis; one patient in each group withdrew the informed consent; of the other three patients in the NMES group, one patient showed agitation, one patient was intubated before the first session, and another patient was misdiagnosed with HF. As a result, a total of 73 patients who finished the first session were analysed.

![Patient flow chart](EHF2-6-975-g001){#ehf212504-fig-0001}

The baseline characteristics of the NMES (*n* = 34) and control (*n* = 39) groups are presented in *Table* [1](#ehf212504-tbl-0001){ref-type="table"}. The median value of age, duration of hospitalization, and mean LVEF in all subjects were 72 years, 18 days, and 40.4%, respectively. All parameters were not significantly different between the two groups except the prevalence of patients on beta‐blocker upon admission and C‐reactive protein level. The device used by one of the patients who received cardiac resynchronization therapy in the NMES group was cardiac resynchronization therapy with defibrillation. In the first session, nine cases in each group received a 60 min session, and the remaining a 30 min session. Electrical current value of 10% and 20% MVC were 28 (24--37) mA and 48 (39--61) mA in the NMES group, and 26 (21--33) mA and 31 (25--37) mA in the control group (10% MVC, *P* = 0.214; 20% MVC, *P* \< 0.001). Intravenous medications that may affect haemodynamics during the first session are shown in *Table* [2](#ehf212504-tbl-0002){ref-type="table"}. The prevalence of each medication use was not significantly different between both groups. The number of sessions that was adjusted to intensity decrease was nine of 343 sessions in the NMES group and three of 382 sessions in the control group.

###### 

Patient characteristics

                                                  NMES (n = 34)     Controls (n = 39)  P value
  -------------------------------------------- ------------------- ------------------- ---------
  Age (years)                                      75 (62--80)         70 (63--79)     0.650
  Male, *n* (%)                                     25 (73.5)           26 (66.7)      0.524
  Body mass index (kg/m^2^)                     23.6 (20.4--23.8)   23.9 (20.3--26.4)  0.757
  NYHA functional class III/IV                        17/17               16/23        0.486
  Ischaemic aetiology of HF (%)                     12 (35.3)           11 (28.2)      0.515
  Atrial fibrillation (%)                           16 (47.1)           16 (41.0)      0.604
  Prior history of HF hospitalization               9 (26.5)            10 (25.6)      0.936
  Medication, *n* (%)                                                                  
  Beta‐blocker                                      18 (52.9)           6 (15.4)       0.001
  ACE inhibitor or ARB                              15 (44.1)           11 (28.2)      0.157
  Aldosterone blocker                               7 (20.6)            6 (15.8)       0.597
  Diuretic                                          9 (26.5)            9 (23.1)       0.737
  Laboratory data                                                                      
  Haemoglobin (g/dL)                               12.5 ± 2.3          11.9 ± 2.8      0.361
  Blood urea nitrogen (mg/dL)                   18.6 (13.2--22.4)   17.2 (11.5--24.7)  0.969
  Creatinine (mg/dL)                            0.96 (0.81--1.90)   1.03 (0.76--1.53)  0.317
  Na (mEq/L)                                     142 (140--144)      141 (140--144)    0.300
  Albumin (g/dl)                                 3.3 (3.1--3.6)      3.2 (2.9--3.4)    0.113
  Brain natriuretic peptide (pg/mL)              656 (335--1370)     473 (286--1096)   0.177
  C‐reactive protein (mg/dL)                    0.66 (0.33--1.84)   1.53 (0.46--3.15)  0.025
  Systolic BP (mmHg)                                155 ± 40            167 ± 43       0.220
  Implantable cardioverter defibrillator (%)         1 (2.9)             1 (2.6)       1.000
  Cardiac resynchronization therapy (%)              2 (5.9)              0 (0)        0.123
  Pacemaker (%)                                      1 (2.9)             1 (2.6)       1.000
  Diastolic BP (mmHg)                               100 ± 30            100 ± 27       0.958
  HR (b.p.m.)                                     109 (80--140)       106 (86--148)    0.510
  LVEF (%)                                         37.5 ± 15.3         42.9 ± 20.3     0.205
  Hospitalization periods (days)                   20 (16--26)         18 (16--22)     0.431

ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; HF, heart failure; HR, heart rate; LVEF, left ventricular ejection fraction; NMES, neuromuscular electrical stimulation; NYHA, New York Heart Association.

Data are presented as means ± standard deviations, medians (with lower and upper quartiles), or numbers (with percentages), where appropriate.

###### 

Intravenous medication during first neuromuscular electrical stimulation session

                NMES (n = 34)   Controls (n = 39)   P value
  ------------- --------------- ------------------- ---------
  Dobutamine    7 (20.6)        5 (12.8)            0.372
  Milrinone     1 (2.9)         0 (0)               0.466
  Nicardipine   1 (2.9)         2 (5.1)             0.639
  Diltiazem     5 (14.7)        5 (12.8)            0.815
  Landiolol     1 (2.9)         4 (10.3)            0.217
  Nicorandil    0 (0)           1 (2.6)             0.347
  Nitrate       9 (26.5)        11 (28.2)           0.868

NMES, neuromuscular electrical stimulation.

Data are presented as numbers (with percentages).

3.2. Feasibility outcomes of neuromuscular electrical stimulation {#ehf212504-sec-0014}
-----------------------------------------------------------------

Systolic BP during the session increased \>20 mmHg compared to baseline in one patient in the NMES group and three patients in the control group, and systolic BP decreased \>20 mmHg in two patients in the NMES group during the first session. HR increase of \>20 b.p.m. was observed in two patients in the control group during the first session. New‐onset arrhythmia did not occur during all sessions in both groups. AF newly developed in one patient in each group during hospitalization. Three patients in the NMES group dropped out from the planned sessions because of cardiac surgery, cerebral infarction, and elevation of creatine kinase. Six patients in the control group dropped out because of ventricular fibrillation, elevation of creatine kinase, treatment of malignancy that was newly diagnosed during hospitalization, agitation, and refusal (two patients). Thus, the completion rate of the planned sessions until discharge was 91% in the NMES group and 84% in the control group. Above these, we concluded that the feasibility of NMES in patients with AHF was high on the basis of the criteria previously described.

3.3. Haemodynamic change during the session {#ehf212504-sec-0015}
-------------------------------------------

During the first session, BP and HR did not change significantly over time in both groups (*Table* [3](#ehf212504-tbl-0003){ref-type="table"}). In addition, BP and HR variations were not significantly different between the two groups (systolic BP, *P* = 0.958; diastolic BP, *P* = 0.201; HR, *P* = 0.665). Furthermore, there was no difference in BP and HR variations between the two groups even if limited in patients with use of vasodilators (systolic BP, *P* = 0.204; diastolic BP; *P* = 0.270; HR, *P* = 0.514) or inotropes (systolic BP, *P* = 0.514; diastolic BP; *P* = 0.601; HR, *P* = 0.715). In echocardiographic parameters, LVEF, LVDd, LAD, TRPG, and RAP did not exhibit significant change before and after the first session except for LVDd in the control group (*Table* [4](#ehf212504-tbl-0004){ref-type="table"}).

###### 

Cardiovascular response during first neuromuscular electrical stimulation session

                        Rest                 10 min         20 min         30 min         P value        
  --------------------- -------------------- -------------- -------------- -------------- -------------- -------
  NMES                  Systolic BP (mmHg)   117.6 ± 17.1   119.6 ± 21.6   119.1 ± 20.5   114.5 ± 26.6   0.385
  Diastolic BP (mmHg)   69.3 ± 9.5           68.4 ± 11.4    71.0 ± 10.8    70.3 ± 10.8    0.065          
  HR (b.p.m.)           83.3 ± 20.0          83.0 ± 20.2    82.0 ± 19.8    82.5 ± 21.2    0.713          
  Controls              Systolic BP (mmHg)   118.6 ± 16.6   120.3 ± 18.5   120.1 ± 18.3   117.7 ± 25.3   0.355
  Diastolic BP (mmHg)   70.4 ± 16.0          70.5 ± 16.3    70.3 ± 15.6    69.7 ± 15.7    0.829          
  HR (b.p.m.)           88.0 ± 17.3          90.1 ± 23.0    88.2 ± 18.0    88.7 ± 22.2    0.627          

BP, blood pressure; HR, heart rate; NMES, neuromuscular electrical stimulation.

Data are presented as means ± standard deviations.

###### 

Echocardiographic parameters before and after first neuromuscular electrical stimulation session

                Before NMES session   After NMES session   P value
  ------------- --------------------- -------------------- ---------
  NMES                                                     
  LVEF (%)      41.7 ± 17.3           43.5 ± 17.1          0.171
  LVDd (mm)     52.5 ± 10.0           52.4 ± 11.2          0.631
  LAD (mm)      42.2 ± 6.3            41.5 ± 6.6           0.159
  *E*/*E*′      24.9 ± 14.9           25.8 ± 15.6          0.602
  TRPG (mmHg)   27.4 ± 6.5            29.0 ± 9.1           0.108
  RAP (mmHg)    8.0 ± 3.7             8.0 ± 3.7            1.000
  Controls                                                 
  LVEF (%)      45.5 ± 18.6           44.6 ± 18.7          0.481
  LVDd (mm)     51.9 ± 9.6            53.1 ± 9.1           0.017
  LAD (mm)      40.5 ± 6.7            40.6 ± 6.4           0.990
  *E*/*E*′      21.2 ± 7.4            19.8 ± 8.5           0.256
  TRPG (mmHg)   26.8 ± 13.0           26.9 ± 13.0          0.964
  RAP (mmHg)    7.3 ± 4.4             6.8 ± 3.4            0.340

*E*/*E*′, ratio of early transmitral flow velocity to early diastolic mitral annular velocity; LAD, left atrial dimension; LVDd, Left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; NMES, neuromuscular electrical stimulation; RAP, right atrial pressure; TRPG, tricuspid regurgitation pressure gradient.

Data are presented as means ± standard deviations, medians (with lower and upper quartiles).

3.4. Adverse effects {#ehf212504-sec-0016}
--------------------

During hospitalization due to AHF, cerebral infarction developed in two patients in the NMES group and one in the control group. Lethal ventricular arrhythmia was documented in two patients in the control group. Two patients showed worsening of HF requiring endotracheal intubation \>24 h after admission, and one patient in the control group died during hospitalization. HF symptom including dyspnoea and fatigue did not change just before and after and during sessions in all cases. No patients showed electromagnetic interference during the first session. Visual analogue scale was 4 cm (1--6 cm) in the NMES group and 3 cm (1--5 cm) in the control group, and there was no significant difference between the two groups (*P* = 0.518).

4. Discussion {#ehf212504-sec-0017}
=============

The findings of our study reveal that NMES is safely implemented in AHF immediately after admission. NMES has been reported to be performed safely limitedly in patients in the intensive care unit or clinically stable patients with chronic HF.[10](#ehf212504-bib-0010){ref-type="ref"}, [11](#ehf212504-bib-0011){ref-type="ref"}, [14](#ehf212504-bib-0014){ref-type="ref"} The present findings demonstrated that NMES can be feasible even in patients with AHF under unstable circulatory dynamics or respiratory conditions. Our results provide evidence on the feasibility of NMES to clinically unstable patients to preserve skeletal muscle function.

Patients with AHF show various BP and HR responses that reflect haemodynamic abnormalities and are both causes and results of AHF. Therefore, BP and HR stabilization is the cornerstone in the management of patients with AHF, and it should be ensured that NMES does not affect these fluctuations. In addition, the agents for AHF treatment such as vasodilators and inotropes also dramatically change these parameters.[19](#ehf212504-bib-0019){ref-type="ref"} Indeed, in this study, 29 (40%) of the patients were receiving vasodilators such as calcium channel blocker or nitrate, and 13 (18%) of the patients were on inotropic agents such as dobutamine or milrinone during the first session. The fact that BP and HR variations were not significantly different between the two groups in patients with the use of vasodilators or inotropes suggests that NMES does not interfere with BP and HR drug management in patients with AHF. In addition, the absence of a difference in visual analogue scale between the NMES and control groups indicates that pain caused by NMES has no effect on haemodynamics.[20](#ehf212504-bib-0020){ref-type="ref"}

Excessive venous return is one of the major concerns for an adverse effect in applying NMES because this may cause an increase in cardiac preload, which worsens HF symptom.[21](#ehf212504-bib-0021){ref-type="ref"} As elevations of RAP and TRPG were not observed in this study, there was no case with exacerbation of HF requiring intubation after admission in the NMES group. Because our NMES protocol was designed to stimulate both sides of the quadriceps and triceps in each extremity alternately, not concurrently, in order to suppress muscle fatigue, it is considered that the rise in venous return to the heart may be within the range that did not affect haemodynamics.

Although AF and ventricular tachycardia are often observed and sometimes become a life‐threatening cause during AHF management,[18](#ehf212504-bib-0018){ref-type="ref"}, [22](#ehf212504-bib-0022){ref-type="ref"} our result revealed that these arrhythmias were not significantly induced by NMES. NMES may not have adverse effects on autonomic nerves and haemodynamics enough to cause arrhythmia because NMES is known to improve sympathetic nerve activity in patients with AHF in addition to less influence on BP, HR, and venous return.[23](#ehf212504-bib-0023){ref-type="ref"} As another mechanism that induces arrhythmias, it is also necessary to evaluate whether NMES directly stimulates the heart or interferes with the pacemakers because implantable cardioverter defibrillators and pacemakers were implanted in several patients with AHF.[18](#ehf212504-bib-0018){ref-type="ref"} As in a previous report,[24](#ehf212504-bib-0024){ref-type="ref"}, [25](#ehf212504-bib-0025){ref-type="ref"} electromagnetic interference was not observed in intracardiac electrocardiogram in our study, indicating that NMES can be safely used in patients with AHF wearing these devices.

This study satisfied all feasibility criteria, which we set up before the study implementation in order to evaluate whether NMES can be safely applied in patients with AHF. We believe that the clinical application of NMES to patients with AHF does not clinically cause problems in safety except for patients wearing mechanical cardiac support.

We must describe several limitations in this study. First, patients with severe HF symptom, or intubated patients, were excluded from enrolment because of inability to acquire informed consent, suggesting selection bias. However, NMES can be feasible and realized technically even using a ventilator. We speculate that the NMES can be expected to be more effective in clinically severe patients because they have difficulty acquiring early ambulation and require long‐term hospitalization. Then, we focused on the feasibility of NMES in patients with AHF, not on endpoint of the skeletal muscle function, because whether NMES can be implemented safely has been a challenge to solve under unstable haemodynamics. Therefore, further study will be necessary to establish the effect on physical function and prognostic effects of NMES in patients with AHF. Nevertheless, we believe that this study provides preliminary data for conducting an intervention study to investigate the effect of skeletal muscle preservation in patients with AHF in the future.

5. Conclusions {#ehf212504-sec-0018}
==============

The present findings demonstrate that NMES can be safely implemented in patients with AHF during the early phase of hospitalization. NMES to patients with AHF under mechanical support of haemodynamics or manifesting severe myocardial electrical instability will be the subject of the future study.
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